Asset profile
Brentuximab Vedotin
Antibody–drug conjugate
Approvedregulatory verdict
Evidence outlook
Approved: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma... (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Weak signal
Featured evidence outside covered markets:NCT01100502 · Disease, Hodgkin · Phase 3 · met primary endpoint · Reliable signalALCANZA (NCT01578499) · Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma · Phase 3 · met primary endpoint · Partial signalNCT01712490 · Hodgkin Lymphoma · Phase 3 · met primary endpoint · Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Brentuximab Vedotin: this drug | Phase 3 | Antibody–drug conjugate | Anti-CD30 antibody-drug conjugate | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK | ||
| Crizotinib | Approved | Small molecule | ALK, ROS1, MET/HGFR, and RON |
…and 45 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(29 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
Phase 2Hodgkin LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT05180097 · CT.gov ↗
What to watch
2027 (13)
January 2027 (2)
April 2027 (1)
Phase 2Hodgkin LymphomaRecruiting
Est. primary completion 2027-04 · NCT06377566 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2CD30-Positive Neoplastic Cells Present, Malignant MesotheliomaActive not recruiting
Est. primary completion 2027-05-01 · NCT03007030 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1/2Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-06-30 · NCT01896999 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Mycosis Fungoides, Lymphomatoid Papulosis, Sezary SyndromeRecruiting
Est. primary completion 2027-07 · NCT03587844 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma …Recruiting
Est. primary completion 2027-08-03 · NCT04745949 · CT.gov ↗
What to watch
October 2027 (3)
Phase 2Relapsed Classic Hodgkin LymphomaRecruiting
Est. primary completion 2027-10-02 · NCT04561206 · CT.gov ↗
What to watch
Phase 2Classical Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-10-03 · NCT05404945 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-10-30 · NCT05922904 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaRecruiting
Est. primary completion 2027-11-30 · NCT05039073 · CT.gov ↗
What to watch
December 2027 (2)
2028 (7)
January 2028 (1)
Phase 2CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Lymphomatoid Papulosis …Active not recruiting
Est. primary completion 2028-01-31 · NCT01352520 · CT.gov ↗
What to watch
March 2028 (1)
Phase 4Hodgkin LymphomaRecruiting
Est. primary completion 2028-03-31 · NCT06831370 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2T-Cell LymphomaRecruiting
Est. primary completion 2028-04-30 · NCT05313243 · CT.gov ↗
What to watch
August 2028 (1)
Early phase / not applicableCD30+ Peripheral T-cell LymphomaRecruiting
Est. primary completion 2028-08-01 · NCT07074457 · CT.gov ↗
What to watch
December 2028 (3)
Phase 3Peripheral T-cell LymphomaEnrolling by invitation
Est. primary completion 2028-12 · NCT07258680 · CT.gov ↗
What to watch
Phase 2EBV-Positive Diffuse Large B-Cell Lymphoma, Nos, Brentuximab VedotinNot yet recruiting
Est. primary completion 2028-12-30 · NCT06925555 · CT.gov ↗
What to watch
Phase 2Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Primary Cutaneous Anaplastic Large Cell LymphomaNot yet recruiting
Est. primary completion 2028-12-30 · NCT07717580 · CT.gov ↗
What to watch
2029 (4)
March 2029 (1)
Phase 2/3Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaNot yet recruiting
Est. primary completion 2029-03-31 · NCT07572123 · CT.gov ↗
What to watch
July 2029 (1)
Phase 2Anaplastic Large Cell Lymphoma, ALK-PositiveRecruiting
Est. primary completion 2029-07-01 · NCT07013565 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Classic Hodgkin LymphomaRecruiting
Est. primary completion 2029-10-20 · NCT07275216 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2/3Classical Hodgkin Lymphoma, Child, Adolescent, Young Adult, Metabolic Response, Survival, Treatment, Brentuximab Vedotin, PET ScanRecruiting
Est. primary completion 2029-11-15 · NCT06563245 · CT.gov ↗
What to watch
2030 (2)
2031 (1)
April 2031 (1)
Phase 3Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8Recruiting
Est. primary completion 2031-04-28 · NCT05675410 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
Phase 3Cutaneous T Cell Lymphoma (CTCL), Brentuximab VedotinNot yet recruiting
Est. primary completion 2032-11-01 · NCT07178457 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.